Floatz logo

Rivogenlecleucel

Cytopenia

Bellicum PharmaceuticalsCell therapyPhase 1/2Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Cytopenia cohort.

Asset / SponsorPhaseRating
Danazol
University of Southern California
Phase 2CCC
VIPIVOTIDE TETRAXETAN
M.D. Anderson Cancer Center
Phase 2CCC
Bpx-501 T Cells
Bellicum Pharmaceuticals
Phase 1/2CC
Rimiducid
Bellicum Pharmaceuticals
Phase 1/2CC

Same molecule, other indications

Rivogenlecleucel is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
inborn error of immunityDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →